PO-1825: Abiraterone sensitises response to high dose radiotherapy in prostate & bone cancer models in vitro.

T.  Wright; K. Prise; A. Cole

doi:10.1016/S0167-8140(21)01843-0

PO-1825: Abiraterone sensitises response to high dose radiotherapy in prostate & bone cancer models in vitro.

T. Wright
, K. Prise
, A. Cole

Research output: Contribution to journal › Meeting abstract › peer-review

Abstract

These results indicate the use of Abiraterone in combination with high dose x-ray radiation could potentially lead to improved tumour cell death and thus better clinical outcomes in a metastatic-castration resistant prostate cancer setting.

Original language	English
Article number	S1018
Journal	Radiotherapy and Oncology
Volume	152
Issue number	Supplement 1
DOIs	https://doi.org/10.1016/S0167-8140(21)01843-0
Publication status	Published - 01 Nov 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S0167-8140(21)01843-0Licence: Unspecified

Cite this

@article{79e22523bd034474a0fc3ef2997abaea,

title = "PO-1825: Abiraterone sensitises response to high dose radiotherapy in prostate \& bone cancer models in vitro.",

abstract = "These results indicate the use of Abiraterone in combination with high dose x-ray radiation could potentially lead to improved tumour cell death and thus better clinical outcomes in a metastatic-castration resistant prostate cancer setting.",

author = "T. Wright and K. Prise and A. Cole",

year = "2020",

month = nov,

day = "1",

doi = "10.1016/S0167-8140(21)01843-0",

language = "English",

volume = "152",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

number = "Supplement 1",

}

TY - JOUR

T1 - PO-1825: Abiraterone sensitises response to high dose radiotherapy in prostate & bone cancer models in vitro.

AU - Wright, T.

AU - Prise, K.

AU - Cole, A.

PY - 2020/11/1

Y1 - 2020/11/1

N2 - These results indicate the use of Abiraterone in combination with high dose x-ray radiation could potentially lead to improved tumour cell death and thus better clinical outcomes in a metastatic-castration resistant prostate cancer setting.

AB - These results indicate the use of Abiraterone in combination with high dose x-ray radiation could potentially lead to improved tumour cell death and thus better clinical outcomes in a metastatic-castration resistant prostate cancer setting.

U2 - 10.1016/S0167-8140(21)01843-0

DO - 10.1016/S0167-8140(21)01843-0

M3 - Meeting abstract

SN - 0167-8140

VL - 152

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - Supplement 1

M1 - S1018

ER -

PO-1825: Abiraterone sensitises response to high dose radiotherapy in prostate & bone cancer models in vitro.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this